207 related articles for article (PubMed ID: 1904333)
1. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
Jones PH; Farmer JA; Cressman MD; McKenney JM; Wright JT; Proctor JD; Berkson DM; Farnham DJ; Wolfson PM; Colfer HT
Clin Cardiol; 1991 Feb; 14(2):146-51. PubMed ID: 1904333
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
Hunninghake DB; Mellies MJ; Goldberg AC; Kuo PT; Kostis JB; Schrott HG; Insull W; Pan HY
Atherosclerosis; 1990 Dec; 85(2-3):219-27. PubMed ID: 2129319
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.
Crepaldi G; Baggio G; Arca M; Avellone G; Avogaro P; Bittolo Bon G; Bompiani GD; Capurso A; Cattin L; D'Alŏ G
Arch Intern Med; 1991 Jan; 151(1):146-52. PubMed ID: 1898694
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
Pan HY; DeVault AR; Swites BJ; Whigan D; Ivashkiv E; Willard DA; Brescia D
Clin Pharmacol Ther; 1990 Aug; 48(2):201-7. PubMed ID: 2116260
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of low-dose pravastatin and squalene, alone and in combination, in elderly patients with hypercholesterolemia.
Chan P; Tomlinson B; Lee CB; Lee YS
J Clin Pharmacol; 1996 May; 36(5):422-7. PubMed ID: 8739021
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
Jacotot B; Benghozi R; Pfister P; Holmes D
Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
[TBL] [Abstract][Full Text] [Related]
11. Influence of cholesterol-lowering on plasma membrane lipids and function.
Lijnen P; Echevaría-Vázquez D; Petrov V
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
[TBL] [Abstract][Full Text] [Related]
12. The effect of pravastatin in relation to low density lipoprotein receptor activity.
Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini S; Bon GB; Campbell LM; Farnier M; Langan J; Mahla G; Pauciullo P; Sirtori C; Egros F; Fayyad R; Nawrocki JW
Atherosclerosis; 1997 Apr; 130(1-2):191-7. PubMed ID: 9126664
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia.
Pan HY; DeVault AR; Brescia D; Willard DA
Clin Ther; 1991; 13(3):368-72. PubMed ID: 1954638
[TBL] [Abstract][Full Text] [Related]
16. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Tobert JA
Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Steinhagen-Thiessen E
Cardiology; 1994; 85(3-4):244-54. PubMed ID: 7987882
[TBL] [Abstract][Full Text] [Related]
18. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
Wang KY; Ting CT
Jpn Heart J; 2001 Nov; 42(6):725-38. PubMed ID: 11933922
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
